

APEC Roundtable Dialogue on Global Regulatory Convergence for Medical Devices & Accelerating Digital Health Regulatory Convergence in the Asia-Pacific

November 08 - 10 2022 | Seoul, Korea (Hybrid format)

DRAFT

APEC Roundtable Dialogue

Workshop on Global Regulatory Convergence for Medical Devices

Day One: November 8, 2022 (COEX 402 / Webex)

<i>Advancing Global Regulatory Convergence for Medical Devices and IVDs</i>	
10:30 – 10:45 AM	<p>Coffee/Tea Break Following Conclusion of Soonchunhyang University APEC Center of Excellence Workshop</p> <p>In person participants: Registration and coffee/tea Virtual participants: Join virtual meeting using [Link will be provided to all registered participants]</p>
10:45 – 10:55 AM (10 minutes)	<p>Host: <u>AHC Representative</u></p> <p>Welcome Remarks: Roundtable objectives and event structure (5 minutes each)</p> <ul style="list-style-type: none"> • Representative, Title, AHC
<i>Session I: Review of Outcomes and Recommendations from November 2021 Dialogue on Regulatory Flexibilities During COVID-19</i>	
10:55 – 11:30 AM (35 minutes)	<p>Presentation: (25 minutes / 10 minutes Q&A)</p> <ul style="list-style-type: none"> • Janet Trunzo, Senior Executive Vice President, Technology and Regulatory Affairs, AdvaMed <p>Identified key regulatory flexibilities during COVID-19 included:</p> <ul style="list-style-type: none"> • Expedited and prioritized review of qualifying products, such as through emergency use pathways; • Adding reliance pathways; • Having flexible clinical trial requirements; and • Adopting digital tools, including permitting electronic submissions and remote inspections. <p>Opportunities included:</p> <ul style="list-style-type: none"> • advancing regulatory reliance and convergence; • adopting agile premarket pathways; • adopting policies that enable alternative sources of evidence; • developing a common emergency use pathway; • adopting state-of-the-art digital technologies; and • facilitating public-private partnerships.

Session II: Review of International Foundational Best Practices and Guidance Documents that Enable the Recommendations of the November 2021 Dialogue

WHO Guidance Documents and Global Model Regulatory Framework

<p>11:30 AM – 12:00 PM (30 minutes)</p>	<p>Presentations: (20 minutes / 10 minutes Q&A)</p> <ul style="list-style-type: none"> • Agnes Kijo, Technical officer, Regulation and Safety Unit, World Health Organization <p>This presentation will overview:</p> <ul style="list-style-type: none"> • Global Model Regulatory Framework • Good reliance practices in the regulation of medical products – Annex 10, WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-Fifth Report • Good regulatory practices in the regulation of medical products – Annex 11, WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-Fifth Report
---	--

IMDRF Guidance Documents

<p>12:00 – 12:30 PM (30 minutes)</p>	<p>Presentations: (20 minutes / 10 minutes Q&A)</p> <ul style="list-style-type: none"> • Melissa Torres, Associate Director for International Affairs, Center for Devices and Radiological Health, U.S. FDA <p>Topics the presentation will cover include:</p> <ul style="list-style-type: none"> • Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices • Principles of Labelling for Medical Devices and IVD Medical Devices • Principles Conformity Assessment for IVD Medical Devices • Medical Device Single Audit Program (MDSAP)
<p>12:30 – 1:15 PM (45 minutes)</p>	<p>Lunch</p>

Session III: Panel Discussion on the Implementation of Identified Foundational Best Practices and Guidance Documents to Advance Regulatory Convergence	
1:15 – 2:20 PM (55 minutes)	<p>The panel will review the key takeaways and recommendations from Session II.</p> <p>Panelists:</p> <p>Regulatory Perspective:</p> <ul style="list-style-type: none"> • Agnes Kijo, Technical officer, Regulation and Safety Unit, World Health Organization <p>Industry Perspectives:</p> <ul style="list-style-type: none"> • Tammy Steuerwald, Global Head of Regulatory Policy, Foundational Principles & Supranational Organizations <p>15 min Opening Statements (5 min each) 25 min Facilitated discussion around prepared questions 15 min Q&A</p> <ul style="list-style-type: none"> • Moderator: Sandra Ligia González, Executive Secretary, Inter-American Coalition for Regulatory Convergence in the Medical Technology Sector
2:20 – 2:35 PM (15 minutes)	Coffee / tea break
In-Person Regulatory & Industry Dialogue Sessions	
2:35 – 3:20 PM (45 minutes)	<p>Case Study 1: Singapore/Thailand Reliance Pilot</p> <ul style="list-style-type: none"> • <i>During COVID-19, Singapore and Thailand undertook an abridged review of their reliance pilot and how it resulted in new regulation</i> • <i>Review of how the pilot and subsequent regulations impacted patient access</i> <p>Q&A</p> <p>Presenter 1: Miang Tanakasemsub, Head of Regulatory Affairs, J&J Presenter 2: Patcharaporn Nontasawadsri, Pharmacist, practitioner level, Pre-Marketing Sub-Division, Medical Devices Control Division, FDA, Thailand Presenter 3: Dr. Lakshmidevi Balakrishnan, Regulatory Consultant, Medical Devices Branch, Singapore Health Sciences Authority</p>

<p>3:20 – 3:50 PM (30 minutes)</p>	<p>Case Study 2: Canada & U.S. and the Use of Digital Tools for Premarket Electronic Submissions and Remote Inspections</p> <ul style="list-style-type: none"> • <i>The use of remote inspections proved invaluable in the fight and recovery from COVID-19. Looking forward, the U.S. FDA speaks to the use of remote inspections beyond the pandemic.</i> • <i>Health Canada speaks to the use of electronic submissions in facilitating premarket review and its role in universal dossiers.</i> <p>Q&A</p> <p>Presenter : Jesus Rueda, Strategies, Special Projects & International Affairs, MedTech Europe</p>
<p>3:50 – 4:20 PM (30 minutes)</p>	<p>Case Study 3: Republic of Korea and the Benefits of Emergency Use Authorizations (EUA)</p> <ul style="list-style-type: none"> • <i>The Republic of Korea overviews its use of EUAs during the pandemic and the benefits of regulatory flexibilities</i> <p>Q&A</p> <p>Presenter: Dr. Ho-Sang Jeong, Director, In Vitro Diagnostic Devices Division, NIFDS MFDS</p>
<p>4:20 – 4:30 PM (10 minutes)</p>	<p>Day One In-Person Program Closing</p>

Day Two: November 9, 2022 (COEX 402 / Webex)

Review of Best Practices and Opportunities for Regulatory Innovation	
8:45 – 9:00 AM	<p>In person participants: Registration and coffee/tea</p> <p>Virtual participants: Join virtual meeting using [Link will be provided to all registered participants]</p>
Session I: Deep Dive into the Medical Device Single Audit Program	
9:00 – 9:40 AM (40 min)	<p>Presentation: (30minutes / 10minutes Q&A) on the Medical Device Single Audit Program (MDSAP)</p> <p>Regulatory Perspective:</p> <ul style="list-style-type: none"> • Kenneth Chen, Senior Regulatory Officer, U.S. FDA
Session II: Opportunities for Innovation	
9:40 – 10:30 AM (50 minutes)	<p>Expanding Patient Access Based on Lessons Learned</p> <p><i>During the November 2021 roundtable, participants identified key regulatory flexibilities and opportunities to implement lessons learned from COVID-19. This session will feature a presentation on the importance of global regulatory convergence and reliance in expand patient access to vital medical technologies. Thereafter, a panel discussion will seek to synthesize the workshop’s recommendations and identify additional opportunities for global regulatory convergence and reliance.</i></p> <p>Moderator: Sandra Ligia González, Executive Secretary, Inter-American Coalition for Regulatory Convergence in the Medical Technology Sector</p> <p>Panelists:</p> <ul style="list-style-type: none"> • Agnes Kijo, Technical officer, Regulation and Safety Unit, World Health Organization • Eric Woo, Regional Director, Asia Pacific, ECRI Institute • Jesus Rueda, Strategies, Special Projects & International Affairs, MedTech Europe • Janet Trunzo, Senior Executive Vice President, Technology and Regulatory Affairs, AdvaMed • You Kyong Lee, Professor, Soonchunhyang University & Director, SCH APEC CoE Team
	Q&A (10 minutes)
10:30 – 10:40 AM (10 minutes)	<ul style="list-style-type: none"> • Day Two In-Person Program Closing

APEC Roundtable Dialogue on Accelerating Digital Health Regulatory Convergence in the Asia-Pacific: Overview of Key IMDRF Documents & Opportunities for Post-Pandemic Regulatory Innovation & Convergence

Day Two: November 9, 2022 (COEX 402 / Webex)

Opening & Introduction	
1:30 – 1:45 PM (15 minutes)	<p>Host: AHC Representative</p> <p>Welcome Remarks: Roundtable objectives and event structure (7.5 minutes each)</p> <ul style="list-style-type: none"> • Representative, Title, AHC • Maggie Henkin, CMI
SaMD Qualification	
1:45 – 2:15 PM (30 minutes)	<p>Presentations: Landscape (20 minutes / 10 minutes Q&A)</p> <ul style="list-style-type: none"> • Sharad Shukla, Director, Regulatory Affairs, MedTech, Johnson & Johnson • Moderator: Maggie Henkin, CMI
2:15 – 2:45 PM (30 minutes)	<p>Presentations: SaMD Risk Classification (20 minutes / 10 minutes Q&A)</p> <ul style="list-style-type: none"> • Dr. Sethuraman Rama, Director, Medical Devices Branch, Health Sciences Authority (HSA) <ul style="list-style-type: none"> ○ HSA's Guidance "Guidelines on Risk Classification of Standalone Medical Mobile Applications and Qualification of Clinical Decision Support Software (CDSS)", published in April 2022 • Moderator: Maggie Henkin, CMI
Regulatory & Industry Dialogue Sessions	
2:45 – 3:45 PM (60 minutes)	<p>Dialogue Session 1: Regulation of Software as Medical Devices – Software Qualification (40 minutes / 20 minutes Q&A)</p> <p>Topic : Considerations for Determining if a product is regulated as a device</p> <p>Panel</p> <ul style="list-style-type: none"> • Dr. Sethuraman Rama, Director, Medical Devices Branch, HSA, Singapore • Dr. David Hau, Senior Medical Adviser, Medical Devices Authorisation Branch at Therapeutic Goods Administration, Australia (IMDRF SaMD Working Group)

	<ul style="list-style-type: none"> • Kitty Mao, Director of Regulatory Affairs, Asia Pacific, GE Healthcare • <u>Moderator</u> : MinYong Choi, Consultant
3:45 – 4:00 PM (15 minutes)	Coffee / Tea Break
4:00 – 5:00 PM (60 minutes)	<p>Dialogue Session 2: SaMD Risk Classification (40 minutes / 20 minutes Q&A)</p> <p>Topic: The benefits of the IMDRF risk classification document. Addressing the challenges of applying the IMDRF concepts</p> <p>Panel</p> <ul style="list-style-type: none"> • Dr. Sethuraman Rama, Director, Medical Devices Branch, HSA, Singapore • Dr. David Hau, Senior Medical Adviser, Medical Devices Authorisation Branch at Therapeutic Goods Administration, Australia (IMDRF SaMD Working Group) • Sharad Shukla, Director, Regulatory Affairs, MedTech, Johnson & Johnson • <u>Moderator</u> : Dr. MinYoung Kim, Professor, Department of Rehabilitation Medicine, CHA Medical Center

Day Three: November 10, 2022 (COEX 301 / Webex)

Opening & Introduction	
8:45 – 9:00 AM (15 minutes)	<p>In person participants: Registration and coffee/tea</p> <p>Virtual participants: Join virtual meeting using [Link will be provided to all registered participants]</p>
Software Products with Multiple Functions	
9:00 – 9:30 AM (30 minutes)	<p>Presentations: Software Products with Multiple Functions (20 minutes / 10 minutes Q&A)</p> <ul style="list-style-type: none"> • Brendan O’Leary, Acting Director, Digital Health Center of Excellence, FDA, USA <ul style="list-style-type: none"> ○ U.S. Food and Drug Administration (FDA) – Multiple Function Device Products: Policy and Considerations Guidance for Industry and Food and Drug Administration Staff • Thierry Sirdey, Head, Department for Medical Devices and Cosmetics and In Vitro Diagnostic Devices, National Agency for the Safety of Medicines and Health Products, France (remote) <ul style="list-style-type: none"> ○ <u>Moderator:</u> Maggie Henkin, CMI (in-person)

Total Product Life Cycle Management	
9:30 – 10:00 AM (30 minutes)	<p><u>Presentations: Considerations for SaMD and SiMD – Alignment of approaches</u> (20 minutes / 10 minutes Q&A)</p> <ul style="list-style-type: none"> • Allan Chuan Qin, Senior Regulatory Affairs Manager for Software Products, China, GE Healthcare: Alignment of SaMD and SiMD
10:00 – 10:15 AM (15 minutes)	Coffee / Tea Break
10:15 – 11:15 AM (60 minutes)	<p><u>Presentations: Change Management</u> (20 minutes / 40 minutes Q&A)</p> <ul style="list-style-type: none"> • Brendan O’Leary, Acting Director, Digital Health Center of Excellence, FDA, USA <ul style="list-style-type: none"> ○ US FDA – AI/ML-Based SaMD Action Plan ○ US FDA's Discussion Paper – Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) • Cassie Scherer, Senior Director of Digital Health Policy and Regulatory Strategy, Global Regulatory Policy, Medtronic • Moderator: Dr. Jaesoon Choi, Associate professor, Biomedical Engineering, University of Ulsan College of Medicine
Unique Considerations for AI	
11:15 – 12:00 PM (45 minutes)	<p><u>Presentation: Overview of IMDRF AI Technical Documents and Unique Considerations for AI</u> (20 minutes)</p> <ul style="list-style-type: none"> • Youngwoo Bae, Assistant Director, Digital Health Devices Division, Department of Medical Device Evaluation, MFDS • Dr. Camille Vidal, Senior Director of Regulatory Affairs for Software, Digital and Advanced Visualization Products, GE Healthcare • Moderator: Maggie Henkin, CMI
12:00 – 12:15 PM (15 minutes)	<p style="text-align: center;">Day Two Hybrid Program Wrap up & Closing Remarks</p> <ul style="list-style-type: none"> • AHC • Maggie Henkin, CMI